The overexpression of the CD163 irritant by tumor-mixed macrophages (TAMs) in the Hodgkin's lymphoma (HL) is considered to be a meaningful predictive biomarker for risk stratum. This is most likely on account of a single nucleotide polymorphism (SNP) at the deoxyribonucleic acid promoter. The aim of this backward-looking case control study was to create a deoxyribonucleic acid expression sketch of a specific biomarker to predict the effect and survival of victims with classic HL (CHL) in Saudi Arabia. The protein expression of CD163 was investigated utilizing immunohistochemistry (IHC). To assess risk stratum, a prognosis index was premeditated for the CD163 protein. This antigen's selected SNPs were genotyped in 100 CHL cases and controls. The study revealed that the CD163 protein verbalization level was significantly equated with disease relapse (DR) and overall continuation (OS), (P <0.001). In addition, the CD163 index threshold (15.0) was erect to be considerably correlated with the relapse rate (P= 0.022). CD163 promotor SNP (rs75608120) shown a significant equivalence with the DR (P=0.032) but not accompanying OS. We concluded that CD163 is a specific biomarker and allure overexpression by TAMs is significantly guide DR and reduced OS.
Author(s) Details:
Huda Al Sayed Ahmed,
Pathology and Laboratory Services Department,
Johns Hopkins Aramco Healthcare, 1709, Dhahran, Saudi Arabia.
Wasim
Fawzi Raslan,
Pathology
and Laboratory Services Department, Johns Hopkins Aramco Healthcare, 10613
Dhahran, Saudi Arabia.
Abdel Halim Salem Deifalla,
Department of Anatomy, College of Medicine and Medical Sciences, Saudi
Arabia.
Mohammad Dahmani Fathallah,
Department of Higher Studies, Arabian Gulf University, 26671 Manama,
Bahrain.
Please see the link here: https://stm.bookpi.org/PRAMR-V10/article/view/9481
No comments:
Post a Comment